Introduction Interindividual differences in drug response are a frequent clinical challenge
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …

The influence of pharmacogenetics in tacrolimus pharmacokinetics and pharmacodynamics
needs further investigation, considering its potential in assisting clinicians to predict the …

ATP-binding cassette (ABC) transporters constitute a superfamily of 48 structurally similar
membrane transporters that mediate the ATP-dependent cellular export of a plethora of …

Immunosuppressant drugs (ISDs) are routinely used in clinical practice to maintain organ
transplant survival. However, these drugs are characterized by a restricted therapeutic …

Aims Long‐term use of the immunosuppressant tacrolimus is limited by nephrotoxicity.
Following renal transplantation, the risk of nephrotoxicity may be determined more by …

Introduction: Tacrolimus-based immunosuppression remains the immunosuppressive drug
of choice in kidney transplantation. Areas covered: Its safety profile is closely linked to its …

Losartan has been shown to be a substrate of the drug-efflux transporter MDR1, encoded by
the ABCB1 gene. ABCB1 c. 2677G> T and c. 3435C> T variants are known to be associated …

Tacrolimus, the most common immunosuppressant for organ transplant, has a narrow
therapeutic range and is metabolized by CYP3A4/5. Trough concentration monitoring and …

Background Tacrolimus (TAC) is the mainstay of immunosuppressive regimen for kidney
transplantations. Its clinical use is complex due to high inter‐individual variations which can …

Tacrolimus is characterized by a highly variable pharmacokinetics (PK) and a small
therapeutic window. It is metabolized specifically by the CYP3A isoenzymes. This study …